News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Navidea Biopharmaceuticals (NAVB) Presents New Data on Precision Diagnostic Platform at Harvard Medical School Conference


9/19/2013 6:39:39 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, presented collaborative data at the Cancer Advance Conference at Harvard Medical School from proof-of-principle imaging studies using tilmanocept-Cy3, a fluorescent-labeled agent from the Company’s Manocept™ platform, utilizing technical principle underlying Navidea’s FDA-approved lymphatic mapping product, Lymphoseek® (technetium 99m tilmanocept) Injection.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES